Skip to content

Biological Monitoring of Nano Sized Particles in the Airways of Asthmatic Children

Biological Monitoring of Nano Sized Particles in the Airways of Asthmatic Children

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01754948
Acronym
EHF
Enrollment
100
Registered
2012-12-21
Start date
2012-07-31
Completion date
2013-06-30
Last updated
2012-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

asthma, reactive airway disease, cough, air pollution, nano particles

Brief summary

Background Ambient airborne particulate material (PM) is defined according the aerodynamic diameter into coarse, fine, and ultrafine or nano sized particles ranging between 2.5-10 µm (coarse), \<2.5 µm (fine), and \<0.1 µm (nano(. Many studies have examined particle effect on respiratory health in children, mainly by environmental monitoring of coarse and fine particles. Biological assessment of individual exposure to nano sized particles in correlation to adverse health effect was not previously studied. Hypothesis individual exposure to nano sized particles in children is associated with reduction in forced expiratory volume at one second.

Interventions

None listed

Sponsors

Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* age 6-18 years * living in the Tel Aviv area * referred to the pulmonology lab for respiratory function evaluation

Exclusion criteria

* Exposure to cigarette smoke * Respiratory infection in the 4 weeks prior to recruitment and testing

Design outcomes

Primary

MeasureTime frameDescription
spirometry values1 secforced expiratory volume at one second

Secondary

MeasureTime frameDescription
methacholine and adenosine challenge test results1 secprovocative concentration causing a 20% fall in forced expiratory volume at one second and provocative dose causing a 20% fall in forced expiratory volume at one second

Countries

Israel

Contacts

Primary ContactShira Benor, MD
shirabenor@yahoo.com+972527360276
Backup ContactElizabeth Fireman, Phd
lizzyf@tlvmc.health.gov.il

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026